Search - tctmd.com

Displaying 521 - 540 of 901

Sort: Relevancy | Date

News Daily News

CHOICE at 1 Year: Sapien, CoreValve Yield Similar Clinical Outcomes

August 11, 2015

News Daily News

CHOICE a 1 Año: Sapien y CoreValve Ofrecen Resultados Clínicos Parecidos

August 11, 2015

News Daily News

一项研究探索了经股动脉TAVR后早出院的安全性

L.A. McKeown

June 24, 2015

News Daily News

Un Estudio Explora la Seguridad del Alta Precoz Post- TAVR Transfemoral

L.A. McKeown

June 24, 2015

News Daily News

Study Explores Safety of Early Discharge After Transfemoral TAVR

L.A. McKeown

June 24, 2015

News Daily News

La FDA Aprueba 2 Nuevos Sistemas TAVR para Pacientes de Alto Riesgo e Inoperable

Yael L. Maxwell

June 24, 2015

News Daily News

FDA 批准 2 项新 TAVR 系统用于治疗高危、无法手术的患者

Yael L. Maxwell

June 24, 2015

News Daily News

FDA Approves 2 New TAVR Systems for High-Risk, Inoperable Patients

Yael L. Maxwell

June 24, 2015

News Daily News

在一项单中心、非随机研究中，Lotus瓣膜的一些指标超过CoreValve

L.A. McKeown

June 17, 2015

News Daily News

Lotus Valve Tops CoreValve on Some Measures in Single-Center, Nonrandomized Study

L.A. McKeown

June 17, 2015

News Daily News

La Válvula Lotus Supera a la CoreValve en Algunos Indicadores en un Estudio No Aleatorizado de un Único Centro

L.A. McKeown

June 17, 2015

News Industry News

Edwards Receives FDA Approval For SAPIEN 3 Transcatheter Heart Valve

June 17, 2015

Presentation TVT 2015

SAPIEN 3 Sizing Considerations: Oversizing, Undersizing, or Volume Reduction

Presenter: John G. Webb

June 05, 2015

Presentation TVT 2015

Technology Essentials, Implantation Guidelines, and SAPIEN 3 Clinical Trial Results

Presenter: Martin B. Leon

June 04, 2015

News Daily News

一个比利时登记处的报告显示，在经股动脉TAVR中采取Sapien、CoreValve时的3年生存率结果相似

Yael L. Maxwell

June 03, 2015

News Daily News

Un Registro Belga Confirma una Supervivencia Similar a los 3 Años con las Válvulas Sapien y CoreValve en la realización de TAVR Transfemorales

Yael L. Maxwell

June 03, 2015

News Daily News

Belgian Registry Reports Similar 3-Year Survival for Sapien, CoreValve in Transfemoral TAVR

Yael L. Maxwell

June 03, 2015

News Daily News

EuroPCR 2015 Takes on TAVR, PCI Optimization, and More

Caitlin E. Cox

May 29, 2015

News Daily News

EuroPCR 2015 Debate las Intervenciones TAVR, la Optimización de las PCI y Más

Caitlin E. Cox

May 29, 2015

News Daily News

2015 年 EuroPCR 还讨论了 TAVR、PCI 优化等内容

Caitlin E. Cox

May 29, 2015

Advertisement

CHOICE at 1 Year: Sapien, CoreValve Yield Similar Clinical Outcomes

CHOICE a 1 Año: Sapien y CoreValve Ofrecen Resultados Clínicos Parecidos

一项研究探索了经股动脉TAVR后早出院的安全性

Un Estudio Explora la Seguridad del Alta Precoz Post- TAVR Transfemoral

Study Explores Safety of Early Discharge After Transfemoral TAVR

La FDA Aprueba 2 Nuevos Sistemas TAVR para Pacientes de Alto Riesgo e Inoperable

FDA 批准 2 项新 TAVR 系统用于治疗高危、无法手术的患者

FDA Approves 2 New TAVR Systems for High-Risk, Inoperable Patients

在一项单中心、非随机研究中，Lotus瓣膜的一些指标超过CoreValve

Lotus Valve Tops CoreValve on Some Measures in Single-Center, Nonrandomized Study

La Válvula Lotus Supera a la CoreValve en Algunos Indicadores en un Estudio No Aleatorizado de un Único Centro

Edwards Receives FDA Approval For SAPIEN 3 Transcatheter Heart Valve

SAPIEN 3 Sizing Considerations: Oversizing, Undersizing, or Volume Reduction

Technology Essentials, Implantation Guidelines, and SAPIEN 3 Clinical Trial Results

一个比利时登记处的报告显示，在经股动脉TAVR中采取Sapien、CoreValve时的3年生存率结果相似

Un Registro Belga Confirma una Supervivencia Similar a los 3 Años con las Válvulas Sapien y CoreValve en la realización de TAVR Transfemorales

Belgian Registry Reports Similar 3-Year Survival for Sapien, CoreValve in Transfemoral TAVR

EuroPCR 2015 Takes on TAVR, PCI Optimization, and More

EuroPCR 2015 Debate las Intervenciones TAVR, la Optimización de las PCI y Más

2015 年 EuroPCR 还讨论了 TAVR、PCI 优化等内容

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content